TY - JOUR
T1 - Genetic and multi-omic resources for Alzheimer disease and related dementia from the Knight Alzheimer Disease Research Center
AU - Fernandez, Maria Victoria
AU - Liu, Menghan
AU - Beric, Aleksandra
AU - Johnson, Matt
AU - Cetin, Arda
AU - Patel, Maulik
AU - Budde, John
AU - Kohlfeld, Pat
AU - Bergmann, Kristy
AU - Lowery, Joseph
AU - Flynn, Allison
AU - Brock, William
AU - Sanchez Montejo, Brenda
AU - Gentsch, Jen
AU - Sykora, Nicholas
AU - Norton, Joanne
AU - Gentsch, Jen
AU - Valdez, Olga
AU - Gorijala, Priyanka
AU - Sanford, Jessie
AU - Sun, Yichen
AU - Wang, Ciyang
AU - Western, Dan
AU - Timsina, Jigyasha
AU - Mangetti Goncalves, Tassia
AU - Do, Anh N.
AU - Sung, Yun Ju
AU - Zhao, Guoyan
AU - Morris, John C.
AU - Moulder, Krista
AU - Holtzman, David M.
AU - Bateman, Randall J.
AU - Karch, Celeste
AU - Hassenstab, Jason
AU - Xiong, Chengjie
AU - Schindler, Suzanne E.
AU - Balls-Berry, Joyce
AU - Benzinger, Tammie L.S.
AU - Perrin, Richard J.
AU - Denny, Andrea
AU - Snider, B. Joy
AU - Stark, Susan L.
AU - Ibanez, Laura
AU - Cruchaga, Carlos
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - The Knight-Alzheimer Disease Research Center (Knight-ADRC) at Washington University in St. Louis has pioneered and led worldwide seminal studies that have expanded our clinical, social, pathological, and molecular understanding of Alzheimer Disease. Over more than 40 years, research volunteers have been recruited to participate in cognitive, neuropsychologic, imaging, fluid biomarkers, genomic and multi-omic studies. Tissue and longitudinal data collected to foster, facilitate, and support research on dementia and aging. The Genetics and high throughput -omics core (GHTO) have collected of more than 26,000 biological samples from 6,625 Knight-ADRC participants. Samples available include longitudinal DNA, RNA, non-fasted plasma, cerebrospinal fluid pellets, and peripheral blood mononuclear cells. The GHTO has performed deep molecular profiling (genomic, transcriptomic, epigenomic, proteomic, and metabolomic) from large number of brain (n = 2,117), CSF (n = 2,012) and blood/plasma (n = 8,265) samples with the goal of identifying novel risk and protective variants, identify novel molecular biomarkers and causal and druggable targets. Overall, the resources available at GHTO support the increase of our understanding of Alzheimer Disease.
AB - The Knight-Alzheimer Disease Research Center (Knight-ADRC) at Washington University in St. Louis has pioneered and led worldwide seminal studies that have expanded our clinical, social, pathological, and molecular understanding of Alzheimer Disease. Over more than 40 years, research volunteers have been recruited to participate in cognitive, neuropsychologic, imaging, fluid biomarkers, genomic and multi-omic studies. Tissue and longitudinal data collected to foster, facilitate, and support research on dementia and aging. The Genetics and high throughput -omics core (GHTO) have collected of more than 26,000 biological samples from 6,625 Knight-ADRC participants. Samples available include longitudinal DNA, RNA, non-fasted plasma, cerebrospinal fluid pellets, and peripheral blood mononuclear cells. The GHTO has performed deep molecular profiling (genomic, transcriptomic, epigenomic, proteomic, and metabolomic) from large number of brain (n = 2,117), CSF (n = 2,012) and blood/plasma (n = 8,265) samples with the goal of identifying novel risk and protective variants, identify novel molecular biomarkers and causal and druggable targets. Overall, the resources available at GHTO support the increase of our understanding of Alzheimer Disease.
UR - http://www.scopus.com/inward/record.url?scp=85198626269&partnerID=8YFLogxK
U2 - 10.1038/s41597-024-03485-9
DO - 10.1038/s41597-024-03485-9
M3 - Article
C2 - 38997326
AN - SCOPUS:85198626269
SN - 2052-4463
VL - 11
JO - Scientific data
JF - Scientific data
IS - 1
M1 - 768
ER -